The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into Cempra Inc. ("Cempra" or the "Company") (NASDAQ: CEMP). The firm's investigation is focusing on whether the Company and/or its officers and directors violated state or federal securities law. On November 2, 2016, the U.S. Food and Drug Administration posted a preliminary review on its website of Cempra's drug, solithromycin, to treat community-acquired bacterial pneumonia highlighting a significant safety signal for hepatotoxicity. On this news, shares of CEMP fell $9.71 per share or over 58% to trading at a low of $6.95 per share on November 2, 2016. If you have suffered a loss in excess of $100,000 from investment in Cempra securities purchased from approximately August 1, 2016 through November 1, 2016, and would like to learn more about Brower Piven's investigation, you may contact Brower Piven either by email at email@example.com or by telephone at (410) 415-6616. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.